We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Collaboration Aims To Identify Optimized Antibodies for Novel Cancer Targets

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "Collaboration Aims To Identify Optimized Antibodies for Novel Cancer Targets"

Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.
Read time:

IONTAS, a company focused on the discovery and optimization of fully human antibodies, has announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells. The agreement is to generate and optimize antibodies for novel immuno-oncology targets, including access to IONTAS’ proprietary Mammalian Display technology to select antibodies with optimal biophysical properties.

IONTAS’ proprietary technology enables the construction of large libraries of stable cell lines displaying human antibodies on their surface. As well as generating therapeutic antibody leads, the technology also aims to address “developability” issues early in discovery; increasing the likelihood of successful progress through the development process. Under the terms of the collaboration, the project provides Adaptate Biotherapeutics with access to IONTAS’ proprietary Mammalian Display technology, allowing the selection of high-affinity antibodies based on their function, stability, expression and developability thereby facilitating a speedy transition through Chemistry, Manufacturing and Controls (CMC) and eventual manufacturing.